Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

[...] upper limit for prior treatment lines in advanced setting. Patients with 1-10% cells with positive IHC for ER in the last recurrent/metastatic site must be treated with at least one line of endocrine therapy in advanced setting. Patients with known germline BRCA1/2 pathogenic variants sho [...]

GasthuiszustersZAS AntwerpenAugustinus

[...] with at least 1 prior cytostatic regimen in advanced setting setting unless treatment with a cytostatic regimen is contraindicated as judged by Investigator. There is no upper limit for prior treatment lines in advan [...] Sodium or potassium outside normal reference range for site. Grade 1 abnormality of sodium and potassium (as defined by CTCAE v5.0) can be included if judged clinically not significant by the investigator, based on the participant's clinical context and comorbidities. Liver disease such as cirrhosis, chronic active hepatitis, o [...] mpaired lung function defined as spirometry and DLCO t [...]

[...] of recurrent, unresectable, locally advanced, or metastatic androgenAR+ receptor (AR) positive Triple Negative Breast Carcinoma (TNBC) AR+ assessed locally and defined as ≥1% of cells staining on Immunohistochemistry (IHC) of last recurrent/metastatic breast cancer specimen Local b [...] ion of last recurrent/metastatic site with positive IHC for Estrogen Receptor (ER) and/or Progesterone Receptor (PR) in ≤10% of cells and negative for Human Epidermal growth factor Receptor 2 (HER2) per American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP)-guidelines Prior invasive (metast [...] [...]